Predicting the outcome of radiotherapy in brain metastasis by integrating the clinical and MRI-based deep learning features.

brain metastasis deep learning magnetic resonance imaging stereotactic radiotherapy therapy outcome prediction

Journal

Medical physics
ISSN: 2473-4209
Titre abrégé: Med Phys
Pays: United States
ID NLM: 0425746

Informations de publication

Date de publication:
Nov 2022
Historique:
revised: 28 05 2022
received: 26 12 2021
accepted: 30 05 2022
pubmed: 22 6 2022
medline: 15 12 2022
entrez: 21 6 2022
Statut: ppublish

Résumé

A considerable proportion of metastatic brain tumors progress locally despite stereotactic radiation treatment, and it can take months before such local progression is evident on follow-up imaging. Prediction of radiotherapy outcome in terms of tumor local failure is crucial for these patients and can facilitate treatment adjustments or allow for early salvage therapies. In this work, a novel deep learning architecture is introduced to predict the outcome of local control/failure in brain metastasis treated with stereotactic radiation therapy using treatment-planning magnetic resonance imaging (MRI) and standard clinical attributes. At the core of the proposed architecture is an InceptionResentV2 network to extract distinct features from each MRI slice for local outcome prediction. A recurrent or transformer network is integrated into the architecture to incorporate spatial dependencies between MRI slices into the predictive modeling. A visualization method based on prediction difference analysis is coupled with the deep learning model to illustrate how different regions of each lesion on MRI contribute to the model's prediction. The model was trained and optimized using the data acquired from 99 patients (116 lesions) and evaluated on an independent test set of 25 patients (40 lesions). The results demonstrate the promising potential of the MRI deep learning features for outcome prediction, outperforming standard clinical variables. The prediction model with only clinical variables demonstrated an area under the receiver operating characteristic curve (AUC) of 0.68. The MRI deep learning models resulted in AUCs in the range of 0.72 to 0.83 depending on the mechanism to integrate information from MRI slices of each lesion. The best prediction performance (AUC = 0.86) was associated with the model that combined the MRI deep learning features with clinical variables and incorporated the inter-slice dependencies using a long short-term memory recurrent network. The visualization results highlighted the importance of tumor/lesion margins in local outcome prediction for brain metastasis. The promising results of this study show the possibility of early prediction of radiotherapy outcome for brain metastasis via deep learning of MRI and clinical attributes at pre-treatment and encourage future studies on larger groups of patients treated with other radiotherapy modalities.

Sections du résumé

BACKGROUND BACKGROUND
A considerable proportion of metastatic brain tumors progress locally despite stereotactic radiation treatment, and it can take months before such local progression is evident on follow-up imaging. Prediction of radiotherapy outcome in terms of tumor local failure is crucial for these patients and can facilitate treatment adjustments or allow for early salvage therapies.
PURPOSE OBJECTIVE
In this work, a novel deep learning architecture is introduced to predict the outcome of local control/failure in brain metastasis treated with stereotactic radiation therapy using treatment-planning magnetic resonance imaging (MRI) and standard clinical attributes.
METHODS METHODS
At the core of the proposed architecture is an InceptionResentV2 network to extract distinct features from each MRI slice for local outcome prediction. A recurrent or transformer network is integrated into the architecture to incorporate spatial dependencies between MRI slices into the predictive modeling. A visualization method based on prediction difference analysis is coupled with the deep learning model to illustrate how different regions of each lesion on MRI contribute to the model's prediction. The model was trained and optimized using the data acquired from 99 patients (116 lesions) and evaluated on an independent test set of 25 patients (40 lesions).
RESULTS RESULTS
The results demonstrate the promising potential of the MRI deep learning features for outcome prediction, outperforming standard clinical variables. The prediction model with only clinical variables demonstrated an area under the receiver operating characteristic curve (AUC) of 0.68. The MRI deep learning models resulted in AUCs in the range of 0.72 to 0.83 depending on the mechanism to integrate information from MRI slices of each lesion. The best prediction performance (AUC = 0.86) was associated with the model that combined the MRI deep learning features with clinical variables and incorporated the inter-slice dependencies using a long short-term memory recurrent network. The visualization results highlighted the importance of tumor/lesion margins in local outcome prediction for brain metastasis.
CONCLUSIONS CONCLUSIONS
The promising results of this study show the possibility of early prediction of radiotherapy outcome for brain metastasis via deep learning of MRI and clinical attributes at pre-treatment and encourage future studies on larger groups of patients treated with other radiotherapy modalities.

Identifiants

pubmed: 35727568
doi: 10.1002/mp.15814
pmc: PMC10083982
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7167-7178

Subventions

Organisme : Natural Sciences and Engineering Research Council of Canada
ID : CRDPJ507521-16
Organisme : Natural Sciences and Engineering Research Council of Canada
ID : RGPIN-2016-06472
Organisme : Lotte and John Hecht Memorial Foundation
Organisme : Terry Fox Foundation
ID : 1083

Informations de copyright

© 2022 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.

Références

Med Phys. 2022 Nov;49(11):7167-7178
pubmed: 35727568
J Neurosurg. 2015 Aug;123(2):373-86
pubmed: 25978710
Front Surg. 2016 May 25;3:30
pubmed: 27252942
JAMA. 2016 Jul 26;316(4):401-409
pubmed: 27458945
Neuro Oncol. 2021 Feb 25;23(2):214-225
pubmed: 33075135
Nat Rev Clin Oncol. 2017 Mar;14(3):169-186
pubmed: 27725679
Neural Netw. 2003 Dec;16(10):1429-51
pubmed: 14622875
Annu Rev Biomed Eng. 2017 Jun 21;19:221-248
pubmed: 28301734
JAMA Oncol. 2017 Jun 01;3(6):827-831
pubmed: 27892978
J Clin Oncol. 2012 Feb 1;30(4):419-25
pubmed: 22203767
Neural Comput. 1997 Nov 15;9(8):1735-80
pubmed: 9377276
Annu Int Conf IEEE Eng Med Biol Soc. 2019 Jul;2019:1022-1025
pubmed: 31946067
IEEE Trans Med Imaging. 2015 Oct;34(10):1993-2024
pubmed: 25494501
Neurosurg Clin N Am. 2011 Jan;22(1):1-6, v
pubmed: 21109143
Med Phys. 2013 Aug;40(8):082901
pubmed: 23927356
Neuro Oncol. 2020 Jun 9;22(6):797-805
pubmed: 31956919
Radiat Oncol. 2009 Mar 04;4:10
pubmed: 19261187
Oncotarget. 2016 Mar 15;7(11):12318-30
pubmed: 26848525
Cancer. 2011 Jun 1;117(11):2505-12
pubmed: 24048799
Neurosurg Clin N Am. 2020 Oct;31(4):481-488
pubmed: 32921345
Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):812-816
pubmed: 29063850
Annu Int Conf IEEE Eng Med Biol Soc. 2020 Jul;2020:1063-1066
pubmed: 33018169
Neurosurgery. 2006 Jul;59(1):86-97; discussion 86-97
pubmed: 16823304
Magn Reson Med. 2017 Sep;78(3):1110-1120
pubmed: 27690156
J Neurooncol. 2014 Sep;119(2):437-43
pubmed: 24996786
J Clin Oncol. 1984 Mar;2(3):187-93
pubmed: 6699671
J Neurooncol. 2017 Oct;135(1):119-127
pubmed: 28669014
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
PLoS Comput Biol. 2020 Sep 14;16(9):e1008193
pubmed: 32925919
IEEE Trans Med Imaging. 2022 Sep;41(9):2228-2237
pubmed: 35320095
Lancet Oncol. 2015 Jun;16(6):e270-8
pubmed: 26065612
Radiother Oncol. 2015 Mar;114(3):345-50
pubmed: 25746350
Lancet Oncol. 2017 Aug;18(8):1049-1060
pubmed: 28687377
Radiat Oncol. 2006 Jun 29;1:20
pubmed: 16808850
Eur Radiol Exp. 2018 Nov 14;2(1):36
pubmed: 30426318
Radiology. 2019 Feb;290(2):479-487
pubmed: 30526358
Sci Rep. 2019 Dec 27;9(1):19830
pubmed: 31882597
Curr Opin Oncol. 2018 Nov;30(6):390-395
pubmed: 30142093
Sci Rep. 2019 Feb 26;9(1):2764
pubmed: 30809047
Cancers (Basel). 2021 Aug 10;13(16):
pubmed: 34439186
Handb Clin Neurol. 2018;149:137-153
pubmed: 29307351
Sci Rep. 2021 Apr 13;11(1):8025
pubmed: 33850222
P T. 2010 Oct;35(10):560-76
pubmed: 21037908
J Clin Oncol. 2018 Feb 10;36(5):483-491
pubmed: 29272161

Auteurs

Seyed Ali Jalalifar (SA)

Department of Electrical Engineering and Computer Science, Lassonde School of Engineering, York University, Toronto, Ontario, Canada.

Hany Soliman (H)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Physical Sciences Platform, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Arjun Sahgal (A)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Physical Sciences Platform, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

Ali Sadeghi-Naini (A)

Department of Electrical Engineering and Computer Science, Lassonde School of Engineering, York University, Toronto, Ontario, Canada.
Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Physical Sciences Platform, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH